Sanofi FDA to review isatuximab as a potential treatment for relapsedrefractory multiple myeloma

Sanofi: FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma

FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma PARIS - July 10, 2019 - The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics ...

More From BioPortfolio on "Sanofi: FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma"